A federal judge denied Teva's bid to delay the first Paragard bellwether trial, keeping a January start date for claims tied ...

The company‘s 2026 guidance and targets for 2027 and beyond should give investors a bit more cause for optimism.

Teva has penned a second pact with Royalty Pharma, this time securing up to $500 million to support the clinical development ...

Under the agreement with Royalty Pharma, the companies will jointly develop the anti-IL-15 antibody, TEV-'408, which is in a ...

If you are wondering whether Teva Pharmaceutical Industries' current share price lines up with its underlying worth, you are in the right place to unpack what the market might be pricing in. Teva's ...

Teva expects 2025 revenues in the lower end of the $16.8–$17.0 billion range ・TEVA stock is on track to open at its highest ...

Teva and Royalty Pharma have signed a deal worth up to $500 million to advance TEV-408, a drug being tested for vitiligo and ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best performing pharma stocks in 2025. Truist lifted the ...

Amid a reorganization campaign that’s breathed new life into hybrid generic and innovative medicines player Teva, the company is leaning into novel medicines and formulations more than ever and ...

As the biopharma industry moves into the new year, Teva is looking to put the past behind it. After proposing a blockbuster $4.25 billion opioid settlement, the drugmaker has secured participation ...

As if Israel’s Teva didn’t have enough troubles on its plate—what with patent losses, pay-for-delay lawsuits, an ongoing CEO search and more—it’s now tangled in a full-blown soap opera with a former U ...